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CONCLUSIONS: The EQ-5D was easily understood and
accepted by this cohort of patients with ACS and can serve as a
valid measure of health-related quality of life in ACS population-
based studies.
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OBJECTIVES: Cough is a widely recognised adverse effect of
Angiotensin-converting enzyme inhibitors (ACEI) and has been
linked to poor medication compliance and potentially poorer
quality of life (QoL). Clinically, AIIRAs (Angiotensin II receptor
antagonists) have been shown to reduce the occurrence of cough
relative to ACEIs. This study was designed to determine the
impact of cough on patients’ QoL by using generic and cough-
speciﬁc QoL measures and contingent valuation (CV) method-
ology. METHODS: Ninety-one patients currently on ACEIs and
48 patients switched from ACEIs to AIIRAs were recruited from
across Australia. Both groups were asked to complete the World
Health Organisation Quality of Life questionnaire (brief version)
(WHOQoL-Bref) and to answer general questions on QoL,
health and demographics. Those on ACEIs also completed the
Cough-speciﬁc Quality of Life Questionnaire (CQLQ). A CV
question, which gave the participants the choice between an
ACEI and AIIRA level of cough, was also asked. The CV health
states were based on clinical trial data. RESULTS: Respondents
ranged in age from 38–81 years (mean = 58.4 years) in the ACEI
group, and 31–82 years (mean = 55.6 years) in the AIIRA group.
A signiﬁcant relationship between cough severity and QoL
existed for the CQLQ (p = 0.003) and the WHOQoL-Bref (p =
0.025) in the ACEI group. Cough severity was signiﬁcantly
related to difﬁculty of sleeping (p = 0.009), being self-conscious
(p = 0.015), and exhaustion (p = 0.002). The CV analysis for the
AIIRA scenario yielded a mean willingness-to-pay of AUS$16.80
per month for those on ACEIs and AUS$16.20 per month for
those on AIIRAs. CONCLUSION: Overall, the results from this
study illustrate the impact that ACEI-induced cough has on
quality of life. Both patient groups were willing to pay over
AUS$16 per month to experience effective hypertension control
associated with a lower risk of experiencing cough. This suggests
that the impact of cough on QoL may be more than previously
considered and should be considered when selecting anti-
hypertensive treatment.
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OBJECTIVE: To assess the acute effects of smoking cessation on
health-related quality of life (HQL). METHODS: Question-
naires were mailed to patients enrolled in a smoking-cessation
program just prior to quit date (T1) and 1-week post-quit (T2).
HQL was assessed by the Smoking Cessation Quality of Life
Questionnaire (SCQoLQ). It contains 5 cessation-targeted scales:
social interactions, self-control, sleep, cognitive-functioning, and
anxiety. The SF-36 is included as a generic core. Other data
included patient demographics, duration of smoking, Fagerstrom
scale, and smoking status at T2. Student’s t-test for paired data
was used to compare the T1–T2 HQL scores. Student’s t-test for
independent samples compared the HQL of a higher addiction
(HA) group (Fagerstrom > 6) to a lower addiction (LA) group
(Fagerstrom < = 6). RESULTS: Respondents (n = 34, 12 in HA-
group, 22 in LA-group) averaged 48.6 (+12.0) years of age and
were primarily Caucasian (97%) and female (72.2%). The mean
Fagerstrom score was 5.0 (+2.3). Overall, one week into cessa-
tion (T1 to T2) there was signiﬁcant worsening in SCQoLQ
anxiety (71.5 + 25.1 to 61.1 + 26.0, p = 0.04) and cognitive-
functioning (72.2 + 20.4 to 61.3 + 23.9, p = 0.02) scores and
improved self-control (46.5 + 22.2 to 5.1 + 18.5, p = 0.001) and
SF-36 general health (65.2 + 18.4 to 70.5+16.9, p = 0.01). At
T1, all LA-group HQL scores were higher than HA-group scores,
signiﬁcantly for sleep, cognitive-functioning, anxiety, and SF-36
role-emotional and mental-health. Between T1 and T2 there was
signiﬁcant decline in sleep, cognitive-function, and anxiety and
improved self-control in the LA-group; the HA-group had sig-
niﬁcant improvement in self-control and SF-36 general-health,
but no signiﬁcant changes in other scores. All SCQoLQ scores
at T2 for LA were higher than either the T1 or T2 SCQoLQ
scores for the HA. CONCLUSIONS: Generally, HQL changes
one-week into a smoking cessation attempt. Smokers with higher
addiction have lower HQL when they begin their cessation
attempt, while smokers with lower addiction have greater change
in their HQL.
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OBJECTIVES: 1) To determine the prevalence of depression
symptoms and to describe antidepressant treatment in a popu-
lation with a history of ACS, and 2) To describe the relationship
of depression treatment adequacy and health-related quality of
life (HRQL) controlling for patient, treatment and disease char-
acteristics. METHODS: All ACS-diagnosed patients discharged
from a university-afﬁliated hospital during a 3-year period were
mailed a survey that included the SF-8, EQ-5D and other self-
reported measures of disease and treatment (e.g. physical func-
tioning, comorbidity, medication compliance, perceived cardiac
severity). Patients were categorized based on self-report of
depressive symptoms and antidepressant medication. Adjusted
mean HRQL measures were determined by least square mean
analysis controlling for independent variables. RESULTS: Of
1217 patients, 490 (40.3%) responded. Respondents averaged
65.2 (± 11.3) years of age; 71% male; 92% Caucasian; 64% with
MI history; 17% had their most recent cardiac event within 6
months. No depressive symptoms and no depression treatment
(without depression) were reported by 59.8%; 27.6% reported
untreated depressive symptoms (untreated); 8.6% reported
depressive symptoms and antidepressant medication (under-
treated); and 4.1% reported no symptoms and antidepressant
medication (adequately treated). Adjusted mean SF-8 Mental
Component Summary (MCS-8) scores were 52.8, 52.5, 42.8, and
40.2 for patients without depression, adequately treated,
untreated, and undertreated respectively (p < 0.0001 for all 
pairwise comparisons except for patients without depression vs.
adequately treated and untreated vs. undertreated). The only
other signiﬁcant pairwise HRQL comparison was between the
adjusted mean general health VAS scores for nondepressed and
